These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 25765695)

  • 1. DPP-4 inhibitors and risk of heart failure EXAMINEd.
    Standl E; Schnell O
    Lancet; 2015 May; 385(9982):2022-4. PubMed ID: 25765695
    [No Abstract]   [Full Text] [Related]  

  • 2. Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS.
    Schernthaner G; Cahn A; Raz I
    Diabetes Care; 2016 Aug; 39 Suppl 2():S210-8. PubMed ID: 27440835
    [No Abstract]   [Full Text] [Related]  

  • 3. Alogliptin (nesina) for type 2 diabetes.
    Med Lett Drugs Ther; 2013 May; 55(1417):41-3. PubMed ID: 23715128
    [No Abstract]   [Full Text] [Related]  

  • 4. [Not Available].
    Van Genechten D; Duh D
    J Pharm Belg; 2015 Dec; (4):33-5. PubMed ID: 26856110
    [No Abstract]   [Full Text] [Related]  

  • 5. US FDA approves three new drugs for Type 2 diabetes.
    Bond T
    Expert Rev Clin Pharmacol; 2013 Mar; 6(2):101. PubMed ID: 23593719
    [No Abstract]   [Full Text] [Related]  

  • 6. New drugs improve glycemic control in type 2 diabetes, but improving heart health remains elusive.
    Mitka M
    JAMA; 2013 Oct; 310(14):1435-6. PubMed ID: 24104360
    [No Abstract]   [Full Text] [Related]  

  • 7. Alogliptin benzoate for management of type 2 diabetes.
    Saisho Y
    Vasc Health Risk Manag; 2015; 11():229-43. PubMed ID: 25914541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.
    Deacon CF
    Curr Opin Investig Drugs; 2008 Apr; 9(4):402-13. PubMed ID: 18393107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canagliflozin, alogliptin benzoate, and ospemifene.
    Hussar DA; Frimpong JO
    J Am Pharm Assoc (2003); 2013; 53(4):442-7. PubMed ID: 23892821
    [No Abstract]   [Full Text] [Related]  

  • 10. [Pharmacological and clinical profile of alogliptin benzoate (NESINA®)].
    Takeuchi K; Fujita T; Hiroi S
    Nihon Yakurigaku Zasshi; 2011 Jan; 137(1):43-50. PubMed ID: 21233588
    [No Abstract]   [Full Text] [Related]  

  • 11. Alogliptin-induced bullous pemphigoid.
    Zafar M; Shahbaz M; Hawley I; Rahmani MJ
    Br J Hosp Med (Lond); 2020 Jul; 81(7):1-3. PubMed ID: 32730152
    [No Abstract]   [Full Text] [Related]  

  • 12. New Treatments for Type 2 Diabetes Mellitus and Cardiovascular Disease. The Revolution Has Begun.
    Simó R; Hernández C
    Rev Esp Cardiol (Engl Ed); 2016 Nov; 69(11):1005-1007. PubMed ID: 27659856
    [No Abstract]   [Full Text] [Related]  

  • 13. [The EXAMINE study].
    Violini R; Vigili de Kreutzenberg S
    G Ital Cardiol (Rome); 2014 Jun; 15(6):340-4. PubMed ID: 25072418
    [No Abstract]   [Full Text] [Related]  

  • 14. Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome.
    Derosa G; Maffioli P
    N Engl J Med; 2016 Mar; 374(11):1095. PubMed ID: 26981947
    [No Abstract]   [Full Text] [Related]  

  • 15. Alogliptin benzoate for the treatment of type 2 diabetes.
    Seino Y; Yabe D
    Expert Opin Pharmacother; 2014 Apr; 15(6):851-63. PubMed ID: 24646052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure.
    Asakawa T; Moritoh Y; Kataoka O; Suzuki N; Takeuchi K; Odaka H
    Life Sci; 2009 Jul; 85(3-4):122-6. PubMed ID: 19427871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus.
    Dudkowski C; Tsai M; Liu J; Zhao Z; Schmidt E; Xie J
    Eur J Clin Pharmacol; 2017 Mar; 73(3):279-288. PubMed ID: 27999883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation.
    Yabe D; Seino Y
    Expert Opin Drug Saf; 2016; 15(2):249-64. PubMed ID: 26607297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alogliptin for the treatment of type 2 diabetes.
    White JR
    Drugs Today (Barc); 2011 Feb; 47(2):99-107. PubMed ID: 21431099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin.
    White WB; Wilson CA; Bakris GL; Bergenstal RM; Cannon CP; Cushman WC; Heller SK; Mehta CR; Nissen SE; Zannad F; Kupfer S;
    Hypertension; 2016 Sep; 68(3):606-13. PubMed ID: 27480840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.